Literature DB >> 24510741

Targeted therapy in gliomas.

Mohamed Ali Hamza1, Mark Gilbert.   

Abstract

The survival outcome of patients with malignant gliomas is still poor, despite advances in surgical techniques, radiation therapy and the development of novel chemotherapeutic agents. The heterogeneity of molecular alterations in signaling pathways involved in the pathogenesis of these tumors contributes significantly to their resistance to treatment. Several molecular targets for therapy have been discovered over the last several years. Therapeutic agents targeting these signaling pathways may provide more effective treatments and may improve survival. This review summarizes the important molecular therapeutic targets and the outcome of published clinical trials involving targeted therapeutic agents in glioma patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24510741     DOI： 10.1007/s11912-014-0379-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  172 in total

1.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

2.  A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.

Authors:  Phioanh Leia Nghiemphu; Patrick Y Wen; Kathleen R Lamborn; Jan Drappatz; H Ian Robins; Karen Fink; Mark G Malkin; Frank S Lieberman; Lisa M DeAngelis; Alejandro Torres-Trejo; Susan M Chang; Lauren Abrey; Howard A Fine; Alexis Demopoulos; Andrew B Lassman; Santosh Kesari; Minesh P Mehta; Michael D Prados; Timothy F Cloughesy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-08       Impact factor: 7.038

3.  Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C.

Authors:  R Marais; Y Light; C Mason; H Paterson; M F Olson; C J Marshall
Journal:  Science       Date:  1998-04-03       Impact factor: 47.728

4.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas.

Authors:  L Snelling; C T Miyamoto; H Bender; L W Brady; Z Steplewski; R Class; J Emrich; M A Rackover
Journal:  Hybridoma       Date:  1995-04

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.

Authors:  Surasak Phuphanich; Kathryn A Carson; Stuart A Grossman; Glenn Lesser; Jeffrey Olson; Tom Mikkelsen; Serena Desideri; Joy D Fisher
Journal:  Neuro Oncol       Date:  2008-05-13       Impact factor: 12.300

8.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

Authors:  Quintino Giorgio D'Alessandris; Nicola Montano; Tonia Cenci; Maurizio Martini; Liverana Lauretti; Federico Bianchi; Luigi Maria Larocca; Giulio Maira; Eduardo Fernandez; Roberto Pallini
Journal:  Acta Neurochir (Wien)       Date:  2012-11-08       Impact factor: 2.216

10.  A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

Authors:  Howard A Fine; Lyndon Kim; Paul S Albert; J Paul Duic; Hilary Ma; Wei Zhang; Tanyifor Tohnya; William D Figg; Cheryl Royce
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531
View more
  16 in total

1.  The discordant method: a novel approach for differential correlation.

Authors:  Charlotte Siska; Russell Bowler; Katerina Kechris
Journal:  Bioinformatics       Date:  2015-10-31       Impact factor: 6.937

2.  Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.

Authors:  Candice D Carpenter; Iyad Alnahhas; Javier Gonzalez; Pierre Giglio; Vinay K Puduvalli
Journal:  Expert Rev Neurother       Date:  2019-05-27       Impact factor: 4.618

3.  Long non-coding RNA SPRY4-IT1 promotes the proliferation and invasion of U251 cells through upregulation of SKA2.

Authors:  Xiao-Jun He; Er-Bao Bian; Chun-Chun Ma; Chao Wang; Hong-Liang Wang; Bing Zhao
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

4.  Long non-coding RNA Fer-1-like family member 4 is overexpressed in human glioblastoma and regulates the tumorigenicity of glioma cells.

Authors:  Feng Ding; Hongtu Tang; Dekang Nie; Liang Xia
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

5.  Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells.

Authors:  Yong Cao; Bin Huang; Changqing Gao
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

6.  Acid-sensing ion channel 1 (ASIC1) mediates weak acid-induced migration of human malignant glioma cells.

Authors:  Yulan Sheng; Baoming Wu; Tiandong Leng; Li Zhu; Zhigang Xiong
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

7.  Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.

Authors:  Esther P Jane; Daniel R Premkumar; Philip A Sutera; Jonathon M Cavaleri; Ian F Pollack
Journal:  Mol Carcinog       Date:  2016-11-22       Impact factor: 5.139

8.  SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Authors:  Marta Mellai; Monica Cattaneo; Alessandra Maria Storaci; Laura Annovazzi; Paola Cassoni; Antonio Melcarne; Pasquale De Blasio; Davide Schiffer; Ida Biunno
Journal:  Oncotarget       Date:  2015-05-20

9.  Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.

Authors:  Ryon H Clarke; Shayan Moosa; Matthew Anzivino; Yi Wang; Desiree Hunt Floyd; Benjamin W Purow; Kevin S Lee
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

10.  circ_0030018 promotes glioma proliferation and metastasis.

Authors:  Yun Shao; Zhengxiang Yang; Weifeng Miao; Xiangrong Yu; Yiping Wu; Yi Pu
Journal:  Transl Neurosci       Date:  2021-06-09       Impact factor: 1.757
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.